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The high mortality rate from gastric
cancer arises from its late detection and
surgical resection at advanced stages
of the disease1. However, particularly in
Japan, mass screening for gastric can-
cer performed by endoscopy and
double-contrast barium X-ray has con-
tributed to early diagnosis and reduc-
tion of mortality from gastric cancer2.
In 1969, Thomson et al.3 successful-
ly demonstrated circulating carcino-
embryonic antigen (CEA) in the sera of
patients with large bowel cancer. This
finding led the way to a new field of
interest in tumor-associated antigens
that could be useful for the early detec-
tion of cancer.
With the advent of monoclonal an-
tibodies4, other tumor markers with spe-
cial application for gastrointestinal tract
malignancies were described. For
adenocarcinoma of the pancreas, CA
19-9 is more specific and sensitive than
CEA, the most widely used tumor
marker5,6. For gastric cancer, CA 72-4
was the marker that showed the higher
sensitivity7. Nonetheless, due to their
low sensitivity and specificity in detect-
ing early primary tumor, tumor markers
have shown little benefit as a method
for screening in the general population.
Tumor markers can be used clini-
cally for the monitoring of tumor recur-
rence and used as prognostic factors
because higher levels have been ob-
served in advanced disease8-10. The
combined assay of preoperative serum
levels of CEA, CA 19-9, and CA 72-4
has provided additional prognostic
information for patients resected for
gastric cancer; patients with preoper-
ative positivity for one of these pos-
sible tumor markers have a high risk of
recurrence, even in the early stages of
gastric cancer10.
The serum level of AFP (alpha-
fetoprotein) has been widely used for
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INTRODUCTION: The clinical importance of preoperative serum levels of CA 72-4, carcinoembryonic antigen (CEA),
CA 19-9, and alpha-fetoprotein (AFP) was prospectively evaluated in 44 patients with gastric cancer.
METHOD: The serum tumor marker levels were determined by commercial radioimmunoassay kits. Positivity for CA 72-
4 (>4 U/mL), CEA (>5 ng/mL), CA 19-9 (>37 U/mL), and AFP (>10 ng/mL) were correlated according to the stage, histology,
and lymph node metastasis.
RESULTS AND DISCUSSION: CA 72-4 showed a higher positivity rate for gastric cancer (47.7%) than CEA (25%), CA
19-9 (25%), and AFP (0%). The combination of CA 72-4 with CEA and CA 19-9 increased the sensitivity to 61.4%. The
positivity rates of CA 72-4 in patients at stages I and II (initial disease) and in patients at stages III and IV (advanced disease)
were 9% and 60.6%, respectively (P < 0.005). No correlation was found between CEA and CA 19-9 levels and the stage of
gastric cancer. There was a tendency of positivity for CA 72-4 to suggest lymph node involvement, but it was not significant
(P = 0.075). Serum levels of tumor markers did not show a correlation with the histological types of gastric cancer.
CONCLUSION: Preoperative serum levels of CA 72-4 provided a predictive value in indicating advanced gastric
cancer.
DESCRIPTORS: Gastric cancer. CEA. CA 72-4. CA 19-9. Alpha-fetoprotein.
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Table 1- Positive rate of CA 72-4, carcinoembryonic antigen (CEA) and CA19-9 in
gastric cancer patients grouped according to initial and advanced disease,
lymphatic invasion and histology.
Gastric cancer CA 72-4 Carcinoembryonic CA 19-9
antigen (CEA)
Initial (stages I/II) n=11 1 (9%) 1(9%) 2 (18.2%)
Advanced (stages III/IV) n=33 20 (60.6%) * 10 (30.3%) 9 (27.3%)
Lymph node invasion (-) n=12 2 (16.7%) 2 (16.7%) 2 (16.7%)
Lymph node invasion (+) n=22 11 (50%) 5 (22.7%) 3 (13.6%)
Diffuse type n= 18 10 (55.6%) 5 (27.8%) 4 (22.2%)
Intestinal type n= 26 11 (42.3%) 6 (23.1%) 7 (26.9%)
*p< 0.005 for CA 72-4
hepatocellular carcinoma screening in
patients with chronic liver disease11-13.
In recent years, many cases of AFP-
producing gastric cancer, characterized
by increased AFP serum levels and
AFP positivity of the gastric cancer
t issues,  have been reported 14 .
Alphafetoprotein-producing gastric
cancer has been associated with a poor
prognosis because of its high prolifera-
tive activity, weak apoptosis, and rich
neovascularization, compared to that of
AFP-negative gastric cancers. These
biological characteristics of AFP-pro-
ducing gastric cancer reflect the aggres-
sive behavior of the tumor and the poor
prognosis of patients with this type of
cancer15.
The purpose of our study was to
determine which marker or combin-
ation of markers among CA 72-4, CEA,
CA 19-9, and AFP would be the most
useful for detecting gastric cancer.
MATERIAL  AND  METHODS
Patients
Forty-four patients with gastric can-
cer were selected for the study. The
average age of patients (27 men, 17
women) was 64.3 + 10.9 years. The tu-
mors were classified as intestinal and
diffuse types, according to Láuren16; 18
patients had the diffuse type and 26
patients had the intestinal type. The
TNM staging was performed accord-
ing to the criteria of the Japanese Classi-
fication of Gastric Cancer17; 4 patients
had stage Ia cancer, 3 patients had
stage Ib, 4 patients stage II, 5 patients
stage IIIa, 13 patients stage IIIb, 8
patients stage IVa, and 7 patients stage
IV.
Serum Markers
Quantitative determinations of CA
72-4, CEA, CA 19-9, and AFP were per-
formed using commercial radioim-
munoassay kits (CIS Bio International,
France). The cut-off values were 5 ng/
mL for CEA, 37 U/mL for CA 19-9, 4 U/
mL for CA 72-4, and 10 ng/mL for AFP.
A result was considered positive when
the marker serum level was higher than
the cut-off value.
Statistics
The serum level of these tumor
markers was investigated with respect
to stage (initial or advanced disease),
regional lymph node metastasis, and
histology (intestinal or diffuse types)
using the chi-square or Fisher exact
test. Gender and age of the patients
were correlated with the stage of the
disease, regional lymph node metasta-
sis, and histology using the chi-square
or Fisher exact test.
RESULTS
Preoperative serum levels of CA 72-
4, CA 19-9, CEA, and AFP were assayed
in 44 patients with gastric cancer. Since
none of the patients were positive for
AFP, the analysis of AFP was excluded.
CA 72-4 was positive in 21 (47.7%) pa-
tients, CEA in 11 (25%) patients, and
CA 19-9 in 11 (25%) patients. The sen-
sitivity of the combination of CA 72-4
and/ or CA 19-9 was 56.8%; of CA 72-4
and/or CEA was 54.5%, and of CEA and/
or CA 19-9 was 43.2%. The three mark-
ers together showed a sensitivity of
61.4%.
CA 72-4 was positive in 9% of pa-
tients at stages I and II (initial disease)
and in 60.6% of patients at stages III
and IV (advanced disease), as shown
in table 1. This difference was signifi-
cant (P < 0.005) when assessed by the
chi-square test. CEA was positive in 9%
of patients with initial disease and in
30% of patients with advanced disease
(P > 0.05). CA 19-9 was positive in 18.2%
of patients with initial disease and in
27.3% of patients with advanced dis-
ease (P > 0.05).
Regarding the lymph node status
of the patients, 12 had no lymphatic in-
vasion and 22 had regional lymph node
metastasis (Table 1). Ten patients who
had advanced disease did not undergo
surgery; thus, they were excluded from
this analysis. CA 72-4 was positive in
11 (50%) patients with lymph node me-
tastasis and in 2 (16.7%) patients nega-
tive for lymphatic invasion (P = 0.075).
CEA was positive in 5 (22.7%) patients
with lymph node metastasis and in 2
(16.7%) patients negative for lymphatic
invasion (P > 0.05). CA 19-9 was posi-
tive in 3 (13.7%) patients with lymph
node metastasis and in 2 (16.7%) pa-
tients negative for lymphatic invasion
(P > 0.05).
There was no correlation of the posi-
tivity rate of CEA, CA 72-4, and CA 19-
9 with the histological types (Table 1).
There was also no correlation of sex
and age to histology, early and ad-
vanced disease, and lymph node inva-
sion (data not shown).
DISCUSSION
The use of tumor markers has be-
come a very attractive method for the
detection and diagnosis of neoplastic
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diseases, as well as for the monitoring
of their course after radical surgery or
during chemotherapy18,19. One of the
challenging problems in the diagnosis
and postoperative follow-up of patients
with gastric cancer is the low sensitiv-
ity of the tumor markers that are cur-
rently being used8.
Since the role of tumor markers in
gastric cancer is still controversial, we
prospectively studied the serum levels
of CA 72-4, CEA, CA 19-9, and AFP in
patients with gastric cancer who were
being evaluated for surgery. Previous
studies of serum levels of CEA, CA 19-
9, and CA 72-4 in gastric cancer have
demonstrated that the positivity of these
markers has a wide range of variation,
from 14% to 42% for CEA 1-8, 10,20-22, from
16% to 38.4% for CA 19-97,8,10,21,22, and
from 24.2% to 45.3% for CA 72-47,9,10,22.
According to our results, CA 72-4
alone presented an even higher posi-
tivity rate (47.7%) than the combination
of CEA and CA 19-9 (43.2%). The best
combination of tumor markers was CA
72-4 and CA 19-9 (56.8%), which was
similar to that of a previous report 23 .
None of the patients were positive for
AFP; the positivity of AFP in gastric
cancer has been reported to be low
(15%)24, and usually, AFP has been a
marker of aggressive behavior tumor
and poor prognosis 15.
When the patients with gastric can-
cer were divided into 2 groups, initial
(stage I/II) and advanced disease
(stage III/IV), CA 72-4 was the best
marker (60.6%) for advanced disease (P
< 0.005). Serum levels of CEA and CA
19-9 exhibited no significant differences
between cases of initial and advanced
disease. The superiority of CA 72-4 for
gastric cancer over CEA and CA 19-9
has been previously demonstrated by
other authors 7,22,23. However, CA 72-4
seems to be a marker of advanced dis-
ease, rather than a marker for mass sur-
vey screening for the detection of early
disease. After curative surgery, CA 72-
4 could be used to monitor recurrence
or metastasis in those cases that had
elevated serum levels prior to surgery.
There was a tendency for CA 72-4
to also be a marker for lymph node
involvement; nonetheless, it was not
significant (P = 0.075). The discrimina-
tion of the lymph node status of the
patients could have clinical applica-
tions for staging. CEA, CA 72-4, and
CA 19-9 were considered markers of
lymph node involvement in other re-
ports 8,10,20. Ikeguchi et al9 found that
CEA was a good indicator of lymph
node metastasis, while CA 72-4 was a
good predictor of peritoneal metasta-
sis. In our study however, CEA and CA
19-9 were neither indicators of lymph
node involvement nor of advanced dis-
ease.
Serum levels of tumor markers
showed no correlation to the histology
of the tumor. Some authors have tried
to explain the low sensitivity of tumor
markers in their studies in terms of the
histology of the tumor, with the diffuse
type of gastric cancer presenting the
lowest positivity rate of the markers21.
However, this correlation is still con-
troversial, since in other reports, the
positivity rate of CEA, CA 72-4, and CA
19-9 was higher in the diffuse type7 .
Nonetheless, other authors have also
shown no correlation between tumor
marker levels and the histology of gas-
tric cancer 10.
The ease of blood sampling makes
serologic tumor marker tests very at-
tractive for the detection of neoplas-
tic diseases. The search for more sen-
sitive methods, along with more spe-
cific and sensitive tumor markers for
gastric cancer, is still under way. A
novel sensitive method, which has
been termed immuno-polymerase
chain reaction (immuno-PCR), was de-
veloped for the detection of gastric
carcinoma-associated antigen MG7-
Ag. The comparison of immuno-PCR
and commercial assays for tumor mark-
ers demonstrated that the sensitivity
of immuno-PCR was 81.4%22.
In conclusion, the results of the cur-
rent study showed that CA 72-4 was the
best marker for advanced gastric cancer;
nevertheless, in the future, more sensitive
techniques using other tumor-associated
antigens should be developed.
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INTRODUÇÃO : A importância
clínica dos níveis séricos pré-operatórios
de CA 72-4, antígeno carcinoembrionário
(CEA), CA 19-9 e alfa-fetoproteína (AFP)
foi avaliada prospectivamente em 44
pacientes com câncer gástrico.
MÉTODOS: Os marcadores tumorais
foram quantificados com o emprego de
kits comerciais de radioimunoensaio. A
positividade dos marcadores, CA 72-4 (>4
U/ml), CEA (>5 ng/ml), CA 19-9 (>37 U/
ml) e AFP (>10 ng/ml), foi correlacionada
com o estágio da doença, a histologia do
tumor e comprometimento de linfonodo.
RESULTADOS E DISCUSSÃO: O
marcador CA 72-4 apresentou maior
positividade para o câncer gástrico
(47,7%) que CEA (25%), CA 19-9 (25%)
e AFP (0%). A associação de CA 72-4,
CEA e CA 19-9 aumentou a
sensibilidade para 61,4%. A
positividade do CA 72-4 nos pacientes
com estágios I e II (Doença Inicial) e
nos pacientes com estágios III e IV
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(Doença Avançada) foi de 9 e 60,6%,
respectivamente (p<0,005). Não foi
observada correlação entre os níveis
séricos de CEA e CA 19-9 com o estágio
do câncer gástrico. O CA 72-4
apresentou tendência de sugerir
comprometimento de linfonodo, mas
não foi significativo (p=0,075). Não
houve correlação entre os níveis
séricos dos marcadores tumorais com
os t ipos histológicos de câncer
gástrico.
CONCLUSÃO: A positividade do CA
72-4 teria o valor de indicar os casos de
câncer gástrico avançado no pré-operatório.
DESCRITORES:  Câncer  gástrico.  CA
72-4.  CEA.  CA 19-9.  Alfa-fetoproteína.
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